Tiago Beites

@tiagobeites.bsky.social

Assistant Researcher | #Tuberculosis research | i3S - University of Porto 🇵🇹 | former Ehrt Lab Weill Cornell Medicine 🇺🇸

Mycobacterium tuberculosis is an outlier in many ways. One of them is keeping a high degree of functional redundancy despite its obligate pathogen lifestyle. In this review, we reflect on the biological meaning of M. tuberculosis functional redundancies. journals.plos.org/plospathogen...

Essential redundancies fuel Mycobacterium tuberculosis adaptation to the host

Redundancy in biology is, at a glance, counterintuitive because if the function of two gene products completely overlaps then, throughout the course of evolution, one of the genes will likely accumula...

journals.plos.org

As the U.S. Government endeavors to make tuberculosis great again, please consider preordering a signed copy of my book about our deadliest infection, its long history, and why in the 75 years since TB became curable, we've allowed over 150,000,000 people to die of the disease. everythingistb.com

cover of my new book everything is tuberculosis: the history and persistence of our deadliest infection

Today is the 24th of March and it's World TB Day. We typically have many activities to educate and raise awareness about TB and how important it is for us all to commit to doing more to end TB! This year feels different though.

A very special one. My dear friends @healycl.bsky.social and @alexandregouzy.bsky.social published a paper with our common mentor @saehrt.bsky.social. On top of that, this is Alex’ first corresponding authorship!! And, of course, excellent bacterial physiology science.

Alexandre Gouzy@alexandregouzy.bsky.social · 2y ago

Happy to share my first ever (co)last author paper 🥳 reporting on how Mtb adapts its carbon diet under acid stress. A big thank you to my partners in crime @saehrt.bsky.social and @healycl.bsky.social without who this would not have been possible 😘 journals.asm.org/doi/10.1128/...

Ignorant drug development question. What’s missing on target-based drug development to make it truly useful? As opposed to the unbiased compound library screens that seem to be the gold standard. I may or may not be thinking on organizing a symposium to address this question.

Asking the void: are there good examples of compounds that targeted both host and pathogen enzymes (homologues) that were successfully modified/optimized to be selective for the pathogen’s enzyme?